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Effects of CCL2 on astrocytic
mRNA expression: microarray analysis
M.W.Zuurman, K.Biber, P. Bakker, C. De Groot and H.W.G.M. Boddeke
Summary
Chemokines are involved in neuroinflammation and activate cells of the central
nervous system (CNS) as well as leukocytes. Astrocytes are a primary source of
chemokines in the brain. In addition, astrocytes also express chemokine recep-
tors. Although, it is known that CCL2 induces several effects in astrocytes, the
expression of its’ primary receptor CCR2 is controversial. Recent evidence
strongly suggests that CCL2 activates an alternative receptor called HCR in
human astrocytes. The aim of the present study was to investigate the effect of
CCL2-induced activation of HCR on the regulation of gene expression in
human adult astrocytes using microarray assays. Surprisingly, we observed a
reduction in expression of genes that belong to the family of metalloproteinases
(MMPs). Subsequent RT-PCR and preliminary Q-PCR studies confirmed the
microarray data and showed down regulation of MMP2, MMP14, MMP16 and
the regulators of MMPs, TIMP1 and TIMP2 after prolonged stimulation with
CCL2 in astrocytes. Since MMPs are important mediators in neuroinflammation
and are involved in the mechanism underlying infiltration of leukocytes in the
CNS, we suggest that CCL2 induces anti-inflammatory activity in astrocytes. 
Introduction
Chemokines are small peptides (8-14 kD) involved in orchestration of the immune sys-
tem. They regulate events such as activation of cellular immune responses and homing
of leukocytes. Chemokines are divided into four subfamilies based on the spatial rela-
tionship of two conserved cysteine residues in their molecular structure (27).
Chemokine signaling is mediated by chemokine receptors that belong to the G-protein
coupled receptor (GPCR) family. Chemokines are clearly involved in the pathology of
neurodegenerative disorders (3). For example, chemokines have been observed to parti-
cipate in multiple sclerosis (MS) (23, 34), Alzheimer’s Disease (11, 32) and stroke (14,
19). Microglia and astrocytes as well as infiltrating leukocytes (T cells and macropha-
ges) produce chemokines and express chemokine receptors under neuroinflammatory
conditions (5, 9, 7, 24). It has been suggested that the CC chemokine CCL2 and its
receptor CCR2 play a role in MS pathology. For example, in tissue affected by MS or
experimental autoimmune encephalomyelitis (EAE) elevated levels of CCL2 are produ-
ced by astrocytes (25, 34). Myelin oligodendrocyte glycoprotein (MOG)- induced EAE
serves as the best model for MS-like pathology to date (7). Interestingly, MOG-immuni-
zed CCL2 -/- and CCR2 -/- mice showed significant reduction in leukocyte infiltrates in
the CNS and no clinical symptoms related to EAE (18, 20). However, although the role
of CCL2 in EAE pathology is evident, the participation of CCR2 in the course of the
disease is of a controversial nature. Recently Gaup and collegues (12) observed no
reduction in physiological and clinical symptoms of EAE in CCR2 -/- mice. In addition,
there have been clear reports of CCR2 independent effects of CCL2 in human smooth
muscle cells and astrocytes (17, 30, 35). Although expression of CCR2 has been shown
in fetal astrocytes (1, 28), we and others did not find CCR2 expression in adult astrocy-
tes (17, 31, 36). We recently provided evidence for a possible alternative CCL2 chemo-
kine receptor in mouse and human astrocytes called L-CCR and HCR, respectively (35,
36). This receptor showed functional CCL2 responses like calcium transients (4, 36)
and changes in F-actin organization (35). In the current study, we examined the possi-
ble effects of HCR on gene expression in adult human astrocytes in response to CCL2.
To this end, we investigated the differential gene expression profile in astrocytes after
prolonged exposure to CCL2 using cDNA microarray technology. Expression of multip-
le genes was altered in astrocytes after stimulation with CCL2. Surprisingly, we obser-
ved a marked reduction in the expression of genes encoding for proteins that belong to
the family of matrix metalloproteinases (MMPs). Based on this finding we suggest that
prolonged stimulation of HCR could reduce expression of MMPs in the brain and there-





Human astrocyte cell cultures were established as described previously (8). In brief, tis-
sue samples from subcortical white matter or cortex were collected and meninges and
visible blood vessels were removed, after which the tissue was minced into cubes of ≤
2 mm3. The tissue fragments were then incubated at 37°C for 20 minutes in a Hank’s
balanced salt solution containing 0.25% w/v porcine trypsin (Sigma, St. Louis, MO),
0.2 mg/ml EDTA., 1 mg/ml glucose and 0.1 mg/ml bovine pancreatic DNase I. After
digestion cell suspensions were gently triturated, washed and taken into culture in
Dulbecco’s Modified Eagle’s Medium (high glucose; Life Technologies, Breda, The
Netherlands) mixed 1 : 1 with L-glutamine containing HAMF10 (Life Technologies,
Breda, The Netherlands) and supplemented with 10% fetal calf serum and 0,01 % peni-
cillin/0.01 streptomycin in a humidified atmosphere (5% CO2) at 37° C. In order to
avoid contamination of astrocyte cultures with meningeal and blood monocyte derived
macrophages, cell suspensions were grown overnight in uncoated tissue flasks allowing
monocytes/macrophages to adhere. The supernatant was then transferred to poly-L-
lysine (15 mg/ml, Sigma)-coated 80 cm2 flasks and after 48h the medium was changed
to remove unattached cells and myelin debris. These cultures now contained 100% ast-
rocytes (GFAP positive cells). Culture medium was refreshed every six days. Cells were
passaged by rinsing the cells with PBS, followed by incubation for 5-10 minutes with
0.2% trypsin at 37°C, washing with culture medium and replating the cells in 25 cm2
flasks. Cells were used only at early passage and not after passage 8. 
cDNA microarray hybridization
CCL2 induced mRNA expression of 1180 genes was assesed using the Atlas (R)
Human Broad 1 cDNA hybridization filter technique provided by Clontech(R). In brief,
in each experiment RNA was isolated from confluently cultured human astrocytes eit-
her treated for 8 hours with recombinant human (rh) CCL2 (1x10-8 M) or from untre-
ated astrocytes, according to Chomczynski and Sacchi (26). The RNA samples were
then treated with DNase I to remove any DNA contamination after the RNA isolation
process and was checked thereafter for potential DNA contamination and integrity by
PCR and gel electrophoresis. Subsequently, 3 microgram of each RNA sample (rhCCL2
treated and untreated) was converted into a 32P-labelled cDNA-probe by reverse trans-
cription (RT) using 32P-ATP. The probes were hybridized overnight on Atlas (R)
Human Broad nylon cDNA filters accoring to the manufacturer’s instructions.
Hybridized filters were then washed and transferred to a Kodak film cassette containing
a phosphoscreen. After two to three days the phosphoscreen was scanned using a
STORM860 phosphoimager from Molecular Dynamics (MD) attached to a personal
computer running MD ImageQuaNT and scanning software. The scans were analyzed
using Clontech Atlas Image (R) software to obtain intensities of all genes present on
each filter. 
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Statistical analysis of cDNA microarray data
Data of independent experiments was normalized using the globalised 10% Trimmed
mean method as recommended for Atlas Human Broad 1.2 gene arrays (22). First,
phosphoimage derived intensities of all genes of individual experiments were ranked in
an ascending manner. Then, the 10% trimmed mean was calculated of intensities of all
genes present on the filter. A simplified formula of the 10% Trimmed Mean is : (1/R)*
[ X(k+1) + X(k+2) +  ...    X(n-k) ], where X is the phospho image intensity of a single
gene, k is n*0.1 and R is the number of remaining observations (total-2k). Thus, in the
10% trimmed mean, the upper and lower 10% extreme values in an ascending range of
values are omitted in the calculation of the mean. The resulting 10% trimmed mean
was then used as scaling factor to normalize intensity values between two filters of the
same experiment. Difference in intensity of a single gene between two filters (in effect a
difference in mRNA expression of a single gene between rhCCL2 treated and non-tre-
ated human astrocytes) was assessed by calculation of the arithmetic difference in nor-
malized phosphoimage gene intensities between treated and untreated astrocytes, and
if possible, as the ratio of the normalized phosphoimage gene intensities (treated/unt-
reated). This normalization method was used to analyse multiple experiments (n=4).  
Reverse transcription and semi-quantative polymerase chain reaction (RT-PCR)
Cells were lysed in guanidinium isothiocyanate/mercaptoethanol buffer and total RNA
was extracted with slight modifications according to Chomczynski and Sacchi (6).
A) Reverse transcription: 1µg of total RNA was transcribed into cDNA as described (2).
For potential contamination by genomic DNA was checked by running the reactions 
(35 cycles) without reverse transcriptase and using GAPDH primers in subsequent 
PCR amplifications. Only RNA samples, which showed no bands after that proce-
dure, were used for further investigation.
B) Polymerase chain reaction: 2µl of the RT-reaction was used in subsequent PCR 
amplification as described (2). Primers for metalloproteinases are listed in Table 6.1.
All sequences were primed at 58°C and with 32 cycles. The housekeeping gene gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) was primed for a 342 bp frag-
ment with 5’- CATCCTGCACCACCAACTGCTTAG-3’ (forward primer) and 5’-
GCCTGCTTCACCACCTTCTTGATG-3’ (backward primer) at 60°C and with 28 
cycles. All oligos were obtained from GenSet Oligos. Cloning into PCR2.1 
(Invitrogen) and subsequent sequencing checked identity of all PCR products.
C) Semi-quantification of PCR results : 20 ml of each PCR-reaction was brought onto a 
2% agarose gel containing ethidium bromide and run for 2 hours. Ultraviolet light 
marked the PCR products on the gel and the visual image was recorded for computer
analysis. Band intensities were calculated using OneDScan software and normalized 




All metalloproteinase primers for Q-PCR were designed with Primer Express®
Software v2.0 (Applied Biosystems) using default parameters (sequences are listed in
Table 6.2). PCR reactions were performed using an ABI Prism 7900HT Sequence
Detection System. Amplification mixtures (25 ml divided over 3 wells, 7 ml per well)
for all genes contained 2 ng cDNA from polyA+RNA template, 1 x SYBR Green PCR
buffer, 3 mM MgCl2, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP 0.4 mM dUTP,
0.025U/ml Amplitaq Gold, 0.01 U/ml AmpErase UNG and 300 nM of each primer. The
cycling conditions comprised 2 minutes AmpErase UNG activity, 10 minutes Amplitaq
Gold activation, 40 cycles at 95°C for 15 seconds and 60°C for 1 minute, and a dissocia-
tion stage: 15 seconds 95°C, 15 seconds 60°C, 15 seconds 95°C ramp rate 2%. A no
template control was included in all experiments.
Real time detection was performed using an ABI PRISM 7900HT Sequence Detection
System and SYBR Green PCR Core Reagents. The mRNA’s of the different genes were
relatively quantified with the Comparative CT Method. The amount of target was nor-
malized to an endogenous reference (RPS29). The threshold was set between 0.4 and
0.6 with a baseline range from 1 to 7. 
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Table 6.1 Primer sequences for RT-PCR
Genename +
productsize Forward primer Backward primer
MMP1 (333bp) GATGGGAGGCAAGTTGAAAA TGCTTGACCCTCAGAGACCT
MMP2 (376bp) TTCCCCTTCTTGTTCAATGG ATTTGTTGCCCAGGAAAGTG
MMP14 (356bp) AGACAAGTTTGGGGCTGAGA AGTGGGTGTCTCCTCCAATG
MMP16 (387bp) CGACGGGAATTTTGTGTTCT TCCTTGAGGATGGATCTTGG
TIMP1 (305bp) CTGTTGTTGCTGTGGCTGAT TGCAGTTTTCCAGCAATGAG
TIMP2 (345bp) CTGGACGTTGGAGGAAAGAA GTCGAGAAACTCCTGCTTGG
Table 6.2 Primer sequences for Quantitative PCR 









Analysis of cDNA microarray data
The 10% Trimmed mean normalization method was powerful in scaling individual gene
expression intensities on two Atlas Human Broad 1.2 filters used in each cDNA micro-
array experiment. Rank-Intensity plots (RIP) showed that compatibility of gene values
on two separate filters was strongly increased after scaling of values to the 10%
Trimmed means of the filters (illustrated for a single experiment in Figure 6.1). The
figure shows that distance between the two plotted curves, which can be regarded as
the artifactual difference between the filters, has been diminished strongly. Indeed, the
10% Trimmed means of total gene intensity of two filters used in each experiment were
significantly equal (data not shown). 
cDNA microarray results
Overall, out of 1180 genes examined 34 genes showed marked upregulation or induc-
tion (table 6.3), whereas 46 genes showed downregulation or inhibition in human ast-
rocytes treated with rhCCL2 for 8 hours, of which the most pronounced have been
shown (Table 6.4). The majority of the genes that were upregulated were intracellular






































Figure 6.1 Rank-intensity plots (RIPs) of the phosphoimage intensities of the genes spotted on two
Atlas Human Broad filters after hybridization with labeled cDNA obtained from CCL2 treated and untre-
ated human astrocytes. A. RIPs of not normalized-gene expression in treated and untreated astrocytes.
The plotted curves show a different global average. This can be observed from the position shift between
the curves. B. RIPs of 10% Trimmed mean normalized-gene expression in gene (and untreated astrocytes.
The plotted curves show a similar shape and position. The global averages of the total normalized gene
intensities are now significantly the same. In each experiment expression of 1180 genes were examined.
Data are taken from a single experiment. 
regulated, 9 genes belong to or are associated with the matrix metalloproteinase system
(Table 6.4). As we regarded the clustered downregulation of metalloproteinases an int-
ruiging finding we examined their expression further in subsequent experiments. 
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Table 6.3 List of genes with higher expression levels in human astrocytes treated with CCL2 (1x10-8 M)
for 8 hours when compared to control astrocytes after 4 independent microarray experiments. 
Gene
14-3-3 protein beta/alpha
AP4 basic helix-loop-helix DNA-binding protein
apoptosis regulator bcl-x
BAD protein
cAMP-dependent protein kinase type I beta regulatory subunit (PRKAR1B)
caspase-3 (CASP3)
cell surface adhesion glycoproteins LFA-1/CR3/p150
colon carcinoma kinase 4 precursor (CCK4) 
cyclin H (CCNH); MO15-associated protein
delta lactoferrin
dihydropyridine-sensitive L-type calcium channel beta-3 subunit (CAB3A/CAB3B)
E16 amino acid transporter 
erythrocyte urea transporter (UTE; UT1
G2/mitotic-specific cyclin G1 (CCNG1; CYCG1)
heme oxygenase 2 (HO2)
homeobox protein hLim1; LHX1
homeobox protein HOX-11
homeobox protein HOX-A5
LIM domain kinase 1 (LIMK-1)
lnk adaptor protein
MPV17 protein
neural cell adhesion molecule phosphatidylinositol-linked isoform precursor (NCAM120)
N-type calcium channel alpha-1B subunit 
nuclear factor I (NFI); NFI-X
nuclear factor NF45
orphan hormone nuclear receptor
phospholipase C-delta-1 (PLC-delta-1; PLCD1)
protein kinase C eta type (NPKC-eta)
serum- & glucocorticoid-regulated serine/threonine protein kinase  (SGK)
transcription factor 11 (TCF11)
transcription factor HTF4
V(D)J recombination activating protein 1 (RAG1)
voltage-gated potassium channel protein KV14
xeroderma pigmentosum group B complementing protein (XPB)
RT-PCR
We examined the mRNA expression of 6 genes of the metalloproteinase family in
human astrocytes stimulated with 1 x 10-8 M CCL2  for 8h. Semi-quantitative PCR
showed that mRNA expression of all 6 genes (MMP1, MMP2, MMP14, MMP16, TIMP1
and TIMP2) were downregulated 8 hours after stimulation (Figure 6.2A). 
Q-PCR
In order to validate the microarray data and the subsequent results from semi-quantitati-
ve RT-PCR assays, we performed quantitative mRNA expression analysis using Q-PCR.
Suppression of the mRNA expression of MMP2, MMP14, MMP16, TIMP1 and TIMP2
was confirmed in astrocytes stimulated for 8 hours with 1 x 10-8 M CCL2. However, Q-
PCR experiments did not confirm the downregulation of MMP1 mRNA expression. 
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Table 6.4 List of genes showing decreased expression in human astrocytes treated with CCL2 (1x10-8 M)
for 8 hours when compared to controls after 4 independent microarray experiments.
Gene
alpha1 catenin (CTNNA1)
beta-2 adrenergic receptor (ADRB2; ADRB2R; B2AR)
Bruton's tyrosine kinase (BTK)
DNA polymerase gamma (POLG)
global transcription activator SNF2L1
growth arrest & DNA-damage-inducible protein 45 gamma (GADD45 gamma)
HLA class I histocompatibility antigen C-4 alpha subunit (HLAC)
inducible nitric oxide synthase (INOS)
interleukin-17 precursor (IL-17)
matrix metalloproteinase 1 (MMP1)
matrix metalloproteinase 12 (MMP12)
matrix metalloproteinase 14 precursor (MMP14)
matrix metalloproteinase 16 precursor (MMP16)
matrix metalloproteinase 8 (MMP8)
metalloproteinase inhibitor 1 precursor (TIMP1)
methionine aminopeptidase 2 (METAP2); 
paired box homeotic protein (PAX8) isoforms 8A/8B + isoforms 8C/8D




ras family member (ras-like protein KIR)
tissue inhibitor of metalloproteinases 2 (TIMP2)
transcription factor ZFM1
ZFM1 protein alternatively spliced product
Discussion
We have examined the gene expression profile of adult human astrocytes stimulated
with 1 x 10-8 M CCL2 for 8 hours. cDNA microarray studies revealed that prolonged
treatment of adult humans astrocytes with CCL2 induced altered gene expression for a
large number of genes. Thus, clearly adult human astrocytes express a CCL2 receptor
that influences astrocytic gene expression. Since astrocytes do not express the known
receptor, CCR2, it is likely that astrocytes respond to CCL2 via another receptor. The
effect of CCL2 on gene expression further confirms our results from a previous study
suggesting that the human orphan chemokine receptor HCR is a functional CCL2 che-
mokine receptor in astrocytes (35). 
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Figure 6.2 mRNA expression of metalloproteinases in adult human astrocytes. A. Semi-quantitative PCR
values of MMP1, MMP2, MMP14, MMP16, TIMP1 and TIMP2 in astrocytes stimulated with 1 x 10-8 M
CCL2 for 8 hours. Data are shown as percentage of control expression levels (baseline at 1). The results
show that expression of all examined genes is downregulated in CCL2 treated astrocytes after 8 hours.
Data are representative for 3 independent experiments. B. Preliminary results of quantitative PCR experi-
ments. Shown are expression values of MMP1, MMP2, MMP14, MMP16, TIMP1 and TIMP2 in astrocytes
stimulated with 1 x 10-8 M CCL2 for 8 hours. Data are shown as percentage of control levels. All genes
except MMP1 show less expression after treatment with CCL2 when compared to control (baseline at 1).
Data are taken from two independent experiments. 
The majority of the genes that were induced after CCL2 treatment were transcription
factors indicating that prolonged treatment with changes transcriptional activity in ast-
rocytes. Which genes are induced by these transcription factors is not known yet and
should be further investigated. Surprisingly, we observed that expression of a large
number of proteins that belong to the metalloproteinase family showed a decrease in
mRNA expression after treatment with CCL2. In subsequent experiments those MMPs
and related proteins that showed the strongest reduction in mRNA expression in cDNA
microarray assays were chosen for further analysis. Semi-quantitative RT-PCR and pre-
liminary Q-PCR data confirmed the microarray study and showed that mRNA expres-
sion of the metalloproteinases MMP2, MMP14, MMP16 and the regulators of  MMPs
TIMP1 and TIMP2 was below control levels after 8 hours of stimulation with CCL2. A
decrease in MMP1 mRNA expression was observed in semi-quantitative RT-PCR expe-
riments, but not in Q-PCR experiments. The reason for this discrepancy is not known
yet and should be further investigated by protein analysis like western blotting or
ELISA.
MMPs are members of a family of at least 15 Zn-dependent endopeptidases. MMPs
regulate normal and pathological tissue remodelling, and activate various proteins (10,
13, 16). Furthermore, MMPs attack the macromolecules of the blood vessel basal lami-
na (29). This reduces the structural integrity of the BBB enabling leukocyte entry that
takes place during neurodegenerative disorders (15). The BBB limits CNS entry of leuk-
ocytes under normal circumstances. Particularly, MMP1 and MMP2 are involved in
leukocyte infiltration of the CNS in neuroinflammatory diseases, such as MS (21). In
addition, MMP1 and MMP2 cleave the chemokines CCL2 and CCL7 respectively to pro-
duce chemokine receptor antagonists. Both chemokines play a role in the pathology of
EAE and MS (26, 31). Our study suggests that astrocytes respond to prolonged expos-
ure to CCL2 initiating an anti-inflammatory cascade that downregulates MMP produc-
tion. With regards to MS/EAE, CCL2 released at inflammatory sites may limit further
break-down of the BBB by limiting MMP release. In this respect, CCL2 may have an
anti-inflammatory role in MS disease progress. Indeed, the levels of CCL2 in CSF
during MS relapse are reduced and a positive correlation between CCL2 levels in the
CSF and reduction in disease severity has been reported (23, 33). At present our data
concern mRNA expression. The extent to which CCL2 stimulation of astrocytes leads
to less MMP protein release has to be elucidated in future experiments. 
In conclusion, prolonged exposure of cultured human astrocytes to CCL2 induced diffe-
rential expression of a large number of genes. Moreover, the observed change in expres-
sion levels occurred in astrocytes that did not express CCR2, the known receptor for
CCL2, suggesting existence of another active CCL2 receptor in human adult astrocytes.
The orphan chemokine receptor HCR is the strongest candidate CCL2 receptor in the
astrocytes. Surprisingly, downregulation of mRNA expression of the metalloproteinases
MMP1 and MMP2, the matrix metalloproteinases MMP14 and MMP16, and the regula-
tors of metalloproteinases TIMP1 and TIMP2 was observed in astrocytes after prolon-
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ged CCL2 exposure. This finding might have implications for MS and other neurodege-
nerative diseases where CCL2 and MMPs are involved. As little is known of chemokine
induced effects of MMP expression in astrocytes, further research is needed to reveal
the underlying mechanism of CCL2 induced downregulation of MMPs in astrocytes.
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